Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
NCT06880081
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
DRUG:
PN20 treatment
Sponsor
Chongqing Peg-Bio Biopharm Co., Ltd.